Population-adjusted indirect comparison (PAIC) of avelumab (AVE) and retifanlimab (RETI) in the first-line (1L) treatment of patients (pts) with metastatic Merkel cell carcinoma (mMCC).

Authors: Mairead Kearney, Karin Tyroller, Loraine Monfort, Vikas Jangra, Hoora Moradian

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.e21513

Source: Full article

e21513